Formulation Characterization and Optimization of Capecitabine and Erlotinib loaded Microsponge for Colon Targeted Drug Delivery System

Abstract

Oral colon emphasized drug delivery systems have become more significant for administering a range of therapeutic drugs both locally and systemically. It is possible for medications to be delivered locally or systemically through the colon. A drug must be protected from gastrointestinal tract degradation in order to be successfully targeted in the colon and to ensure controlled release. There are a number of efficient colon targeting techniques. In order to ensure efficient delivery in the colonic region, an attempt has been made to formulate and characterize the microsponge formulation of Capecitabine and Erlotinib employing quasi-emulsion solvent diffusion technique. If a drug is administered orally using controlled drug delivery systems, it should ideally be possible to achieve the necessary plasma levels and maintain them for an extended amount of time. The best way to distribute protein and peptide drugs systemically is to deliver specifically to the colon, local management of colonic pathologies, amebiosis, colonic malignancy, and other intestine illnesses. It is possible for medications to be delivered locally or systemically through the colon. However, if the drugs are able to reach the colon directly, the systemic adverse effects can be minimized and the treatment can be made more successful. The drugs should be protected by the colonic drug delivery system (CDDS) while it is being transported to colon; that is, it is recommended that the drug be released and absorbed only after the system has reached the colon, neither in the stomach or small intestine, nor should the bioactive agent be broken down in any of the dissolution sites. The goal of the current investigation is to formulate API infused microsponges fabricated by quasi emulsion solvent diffusion technique with several polymers in varying ratio with different stirring speed. It is possible to incorporate drug loaded microsponges in specific dosage form to treat colon cancer. Study also investigated to develop an acceptable, safe, efficacious, st